Detalles de la búsqueda
1.
Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.
BMC Psychiatry
; 12: 222, 2012 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216976
2.
Depression diagnoses following the identification of bipolar disorder: costly incongruent diagnoses.
BMC Psychiatry
; 10: 39, 2010 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-20525372
3.
Costs associated with attempted suicide among individuals with bipolar disorder.
J Ment Health Policy Econ
; 13(2): 87-92, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20919595
4.
Measuring use and cost of care for patients with mood disorders: the utilization and cost inventory.
Med Care
; 47(2): 184-90, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19169119
5.
Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.
Value Health
; 12(5): 708-15, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19508658
6.
Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease.
Am J Health Syst Pharm
; 75(6): 359-366, 2018 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29523532
7.
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
Int J Chron Obstruct Pulmon Dis
; 13: 499-508, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29440887
8.
Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
J Affect Disord
; 101(1-3): 187-93, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17254637
9.
Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Int J Chron Obstruct Pulmon Dis
; 12: 1793-1801, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28694692
10.
Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year.
Clin Ther
; 39(1): 66-74, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28011247
11.
Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.
Neuropsychiatr Dis Treat
; 10: 869-78, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24876779
12.
Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
Neuropsychiatr Dis Treat
; 10: 1287-96, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25031537
13.
The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.
Clinicoecon Outcomes Res
; 5: 407-18, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23983478
14.
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Curr Med Res Opin
; 27(1): 115-22, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21110749
15.
Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.
Curr Med Res Opin
; 26(10): 2475-84, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20825269
16.
Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.
Curr Med Res Opin
; 25(3): 755-64, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19199435
17.
Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis.
J Clin Psychiatry
; 69(5): 749-58, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18363423
18.
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.
Curr Med Res Opin
; 23(1): 97-104, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17257471
19.
Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
Curr Med Res Opin
; 23(11): 2805-14, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17910804
20.
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
J Psychopharmacol
; 19(6 Suppl): 110-7, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16280344